Last updateSun, 27 Sep 2020 6pm

Antares Vision as an innovator for artificial intelligence solutions

Antares Vision together with Orobix designs innovative solutions in the Smart Data age
The challenge in the future across all market segments will be the further development of artificial intelligence. It is not surprising, therefore, that thanks to Antares Vision's expertise, innovative ways of collecting and processing data have been found to generate added value for each individual company. After last year's welcome to the Antares Vision world of Orobix, a company specializing in AI solutions, this year we are already working on innovative solutions in the world of Artificial Intelligence. Not least because these systems play a central role in the digital transformation process of companies.

In 2019, the American Food and Drug Administration (FDA) published a "Discussion Paper" which describes a regulatory proposal for the evaluation of AI-based medical devices. Accordingly, technologies based on artificial intelligence and used for medical purposes fall into the category of software as a medical device (SaMD). From a regulatory point of view, there is a need to create a set of rules capable of accompanying both the process of "continuous learning" and the related modifications of the algorithms, and of providing an adequate level of safety and effectiveness throughout the life cycle of the device. In order to achieve this goal, the software vendor must adhere to appropriate quality standards and best practices within its organisation and throughout the product life cycle to ensure validation of the software. Even possible changes must be recorded so that the patient is fully protected.
Antares Vision, the world's leading supplier of visual inspection systems, track & trace solutions and intelligent data management applies this to individual production lines. This is because the traditional analysis of inspection machines is based on capturing one or more images and searching for specific elements of the product that makes the decision to accept or reject the product. Whether a product is "good" or "bad" is decided according to specific characteristics. It becomes difficult if the product to be tested deviates from the ideal case and is still perfectly acceptable. For example, the detection of a defect on a homogeneous or complex surface where the presence of a different background strongly influences or even disturbs the analysis. Since Artificial Intelligence has the ability to analyze different structures and take into account the human interpretation, AI algorithms are well suited for use in the inspection of tablets. An irregularity of the coating can be rejected if it shows an unexpected pigmentation, but it can also be accepted if it is known that its specific cause does not present any risk, although the irregularity may be even greater than in the first case. Therefore, the introduction of AI in an inspection machine, together with traditional algorithms, leads to the ability to differentiate defects, extend the criteria for defect identification and at the same time reduce false production waste.
Especially in the pharmaceutical sector, many companies deal with Artificial Intelligence, not least in order to react to business problems. Antares Vision is constantly working on new solutions, individually tailored to your needs. So that not only can you gain a competitive advantage thanks to the innovative solutions of the Italian company, but also that your customers are protected. Because one thing is certain, these technologies will change the whole system enormously.


  • Latest Post

  • Most Read

  • Twitter

Who's Online

We have 1175 guests and no members online

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.